A Phase 4 interventional study of HOE901-U300 (Insulin Glargine 300 U/ml) and Lantus (Insulin Glargine 100 U/ml) in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 100 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-03-28.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 24 in phase 4, and was the 48th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 638 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 73 across the 66 interventional studies. Of the 63 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 66 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
67 studies in Diabetes Mellitus, Type 1 by Sanofi: 6 open now, 10 under way, 1 of them phase 3. Of 56 finished, 13 (23%) have results posted.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 4th largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2016, is one of 14 in phase 4, and was the 40th registered.
Sanofi’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 67 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes mellitus.
Secondary Objective:
To demonstrate that treatment with HOE901-U300 compared to Lantus provides:
The maximum study duration per participant was to be of approximately 20 weeks that consisted of an up to a 4-week screening and CGM training period including a 1-2 week baseline (blinded) CGM performance (allowed for re-training), a 14-week open-label, comparative treatment period allowing for dose titration in both basal and meal-time insulin and including a 1-2 week end-of treatment blinded CGM collection with fixed dose of HOE901-U300 and Lantus, and a 2 day post treatment follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participants's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HOE901-U300 (Insulin glargine, 300 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting self-measured plasma glucose (SMPG) levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
Drug: HOE901-U300 (Insulin Glargine 300 U/ml) · Drug: Mandated back ground therapy
Lantus (Insulin glargine, 100 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting SMPG levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
Drug: Lantus (Insulin Glargine 100 U/ml) · Drug: Mandated back ground therapy
Drug page: Insulin Glargine
Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
Also known as: Toujeo
Drug page: Insulin Glargine
Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
Also known as: HOE901-U100
Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGM
The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted least square (LS) means and standard error (SE) were obtained from a generalized linear model with identity link including post baseline CGM assessment during Week 15 (and/or Week 16).
Time frame: During Week 15 and/or 16
Percentage of Participants With Documented Symptomatic Nocturnal Hypoglycemia
Documented symptomatic nocturnal hypoglycemia was defined as an event with typical symptoms of hypoglycemia accompanied by SMPG \<=70 mg/dL that occurred between 00:00 and 05:59 hours as reported on the hypoglycemia electronic case report form (eCRF).
Time frame: Baseline up to Week 16
Documented Symptomatic Nocturnal Hypoglycemia Event Rate Per Participant-Year
Documented symptomatic nocturnal hypoglycemia was defined as an event with typical symptoms of hypoglycemia accompanied by SMPG \<=70 mg/dL that occurred between 00:00 and 05:59 hours as reported on the hypoglycemia eCRF.
Time frame: Baseline up to Week 16
Mean Change From Baseline in Glucose Level During Last 4 Hours of CGM Data Collection Prior to the Next Day Basal Insulin Injection During Week 15 and/or Week 16
Adjusted LS means and SE were obtained from mixed model including post baseline CGM assessment during the last 4 hours prior to the next day's basal insulin injection during Week 15 (and/or Week 16).
Time frame: Baseline, during Week 15 and/or Week 16
Percentage of Time Glucose Concentrations Within the Target Range of 70 to 140 mg/dL During Last 4 Hours of CGM Data Collection Prior to Next Day Basal Insulin Injection
Adjusted LS means and SE were obtained from mixed model including post baseline CGM assessment during the last 4 hours prior to the next day's basal insulin injection during Week 15 (and/or Week 16).
Time frame: During Week 15 and/or Week 16
Coefficient of Variation (CV%) in Mean CGM Glucose
CV% was a measure of spread of variability relative to mean of population. For CGM glucose values over 24 hours, CV% was measure of glycemic variability across 24-hour day and calculated for each period (total, within day and between days) as ratio of standard deviation of glucose values to mean of glucose values.
Time frame: During Week 15 and/or Week 16
Change From Baseline in Daily Insulin Dose at Week 16
Change from Baseline at Week 16 for daily basal insulin dose and daily bolus insulin dose was reported.
Time frame: Baseline, Week 16
The study was conducted at 100 sites in United States. A total of 980 participants were screened between 5 May 2016 and 16 February 2017, of whom 342 were screen failures. Screen failures were mainly due to exclusion criteria met.
| Milestone | HOE901-U300 | Lantus |
|---|---|---|
| Started | 320 | 318 |
| Completed | 291 | 281 |
| Not completed | 29 | 37 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Lack of efficacy | 2 | 2 |
| Withdrew: Poor compliance to protocol | 7 | 4 |
| Withdrew: Hypoglycemia | 2 | 0 |
| Withdrew: Other than specified | 14 | 25 |
| Withdrew: Lost to follow-up | 1 | 5 |
The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted least square (LS) means and standard error (SE) were obtained from a generalized linear model with identity link including post baseline CGM assessment during Week 15 (and/or Week 16).
| percentage of time | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGM | 55.40 ± 1.08 | 55.18 ± 1.10 |
Documented symptomatic nocturnal hypoglycemia was defined as an event with typical symptoms of hypoglycemia accompanied by SMPG \<=70 mg/dL that occurred between 00:00 and 05:59 hours as reported on the hypoglycemia electronic case report form (eCRF).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Documented <=70mg/dL | 70.8 | 68.3 |
| Documented <54 mg/dL | 50.9 | 54.1 |
Documented symptomatic nocturnal hypoglycemia was defined as an event with typical symptoms of hypoglycemia accompanied by SMPG \<=70 mg/dL that occurred between 00:00 and 05:59 hours as reported on the hypoglycemia eCRF.
| events per participant-year | HOE901-U300 | Lantus |
|---|---|---|
| Documented <=70 mg/dL | 11.38 | 11.39 |
| Documented <54 mg/dL | 4.99 | 5.61 |
Adjusted LS means and SE were obtained from mixed model including post baseline CGM assessment during the last 4 hours prior to the next day's basal insulin injection during Week 15 (and/or Week 16).
| mg/dL | HOE901-U300 | Lantus |
|---|---|---|
| Mean Change From Baseline in Glucose Level During Last 4 Hours of CGM Data Collection Prior to the Next Day Basal Insulin Injection During Week 15 and/or Week 16 | -1.99 ± 3.68 | 5.67 ± 3.72 |
Adjusted LS means and SE were obtained from mixed model including post baseline CGM assessment during the last 4 hours prior to the next day's basal insulin injection during Week 15 (and/or Week 16).
| percentage of time | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Time Glucose Concentrations Within the Target Range of 70 to 140 mg/dL During Last 4 Hours of CGM Data Collection Prior to Next Day Basal Insulin Injection | 36.49 ± 1.62 | 35.07 ± 1.65 |
CV% was a measure of spread of variability relative to mean of population. For CGM glucose values over 24 hours, CV% was measure of glycemic variability across 24-hour day and calculated for each period (total, within day and between days) as ratio of standard deviation of glucose values to mean of glucose values.
| percent of mean glucose level | HOE901-U300 | Lantus |
|---|---|---|
| Total CV% | 41.27 ± 0.63 | 40.72 ± 0.64 |
| Within-day CV% | 36.99 ± 0.56 | 36.23 ± 0.56 |
| Between-days CV% | 17.44 ± 0.59 | 17.53 ± 0.60 |
Change from Baseline at Week 16 for daily basal insulin dose and daily bolus insulin dose was reported.
| International Units | HOE901-U300 | Lantus |
|---|---|---|
| Daily basal Insulin Dose | 8.8 ± 11.8 | 7.0 ± 10.1 |
| Daily bolus Insulin Dose | -1.8 ± 11.8 | -3.0 ± 11.3 |
Adjusted LS means and SE were obtained from mixed model including post baseline CGM assessments. Data was reported for participants with an end of study HbA1c \<7.5 or HbA1c \>=7.5% over a 24 hour period.
| minutes | HOE901-U300 | Lantus |
|---|---|---|
| End of study HbA1c <7.5% | 105.84 ± 25.64 | 56.07 ± 25.40 |
| End of study HbA1c >=7.5% | 11.64 ± 27.26 | 31.95 ± 27.57 |
Collected over All Adverse Events (AE) were collected from signature of informed consent form up to study completion (Week 16) regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HOE901-U300 | 0/320 (0%) | 17/320 (5.3%) | 54/320 (16.9%) |
| Lantus | 0/318 (0%) | 14/318 (4.4%) | 54/318 (17%) |
| Event | HOE901-U300 | Lantus |
|---|---|---|
| Hypoglycaemic unconsciousnessNervous system disorders | 6/320 | 3/318 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/320 | 3/318 |
| Hypoglycaemic seizureNervous system disorders | 2/320 | 3/318 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/320 | 3/318 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/320 | 0/318 |
| Acute kidney injuryRenal and urinary disorders | 2/320 | 0/318 |
| Road traffic accidentInjury, poisoning and procedural complications | 2/320 | 1/318 |
| Diabetic foot infectionInfections and infestations | 0/320 | 1/318 |
| GangreneInfections and infestations | 0/320 | 1/318 |
| Hypoglycaemic comaNervous system disorders | 0/320 | 1/318 |
| Event | HOE901-U300 | Lantus |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 28/320 | 28/318 |
| NasopharyngitisInfections and infestations | 27/320 | 27/318 |
Analysis was performed on randomized population that included any participant who had been allocated to a randomized treatment regardless of whether the treatment kit was used or not.
| Age, Continuous(years) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 45.5 ± 14.0 | 45.5 ± 13.9 | 45.5 ± 13.9 |
| Sex: Female, Male(Participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Female | 140 | 138 | 278 |
| Male | 180 | 180 | 360 |
| Ethnicity (NIH/OMB)(Participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Hispanic or Latino | 43 | 42 | 85 |
| Not Hispanic or Latino | 277 | 276 | 553 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 3 |
| Asian | 5 | 3 | 8 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 24 | 28 | 52 |
| White | 281 | 282 | 563 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 4 | 10 |
| Body mass index(kg/m^2) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 27.50 ± 4.88 | 27.65 ± 4.92 | 27.57 ± 4.90 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from May 2016 to primary completion in Jun 2017, 13 months.
Results were first posted in Aug 2018, 1 year 2 months after primary completion.
Of 74 phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine